Related Experiment Video
Updated: Jun 6, 2026
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
[Clinical report on protocol HL-98 for childhood Hodgkin's Lymphoma]
Lu Dong1, Ci Pan, Hui-Liang Xue
1Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
Insights
The HL-98 protocol shows promising results for childhood Hodgkin's lymphoma, with a 5-year event-free survival of 73.7%. Early-stage patients (I and II) achieve good prognoses without radiotherapy.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Trials
Background:
- Childhood Hodgkin's lymphoma (HL) requires effective long-term treatment strategies.
- The HL-98 protocol aimed to standardize and improve outcomes for pediatric HL patients.
Purpose of the Study:
- To evaluate the efficacy and long-term prognosis of the HL-98 treatment protocol in childhood Hodgkin's lymphoma.
- To assess the impact of risk stratification and radiotherapy on patient outcomes.
Main Methods:
- Patients were stratified into low (R1), middle (R2), and high-risk (R3) groups based on clinical factors.
- Chemotherapy courses varied by risk group (4, 6, or 9 courses), with radiotherapy for residual disease.
- Event-free survival (EFS) was analyzed using Kaplan-Meier method for patients diagnosed between 1998 and 2008.
Main Results:
- A total of 26 pediatric patients were enrolled, with a median age of 94.5 months.
- The 5-year event-free survival (EFS) was 73.7%, and overall survival (OS) was 85.9%.
- Complete remission was achieved in 80.76% of patients; relapses occurred in 5 cases, particularly in stage IV with B symptoms.
Conclusions:
- The HL-98 protocol demonstrates a reasonable and good long-term prognosis for childhood Hodgkin's lymphoma.
- Patients diagnosed with early-stage (I and II) Hodgkin's lymphoma can achieve favorable outcomes without the need for radiotherapy.
Objective:
To improve the long-term prognosis of childhood Hodgkin's lymphoma (HL) by standard treatment protocol HL-98.
Methods:
Patients were divided into low (R(1)), middle (R(2)) and high-risk (R(3)) groups based on staging, tumor size and with or without B symptoms. Patients of R(1), R(2) and R(3) groups were given 4, 6, and 9 courses of chemotherapy, respectively. Low dose radiotherapy to involved area was given to patients with residual disease at the end of chemotherapy. All patients diagnosed between 1998 and Dec. 2008 were enrolled. The software of SPSS 11.0 was used and the event free survival (EFS) was generated by Kaplan-Meier.
Results:
There was a total of 26 patients with male 20 and female 6. The average age was 97 (30 to 179) months and median age 94.5 months. Three patients were in stage I, 4 in stage II, 9 in stage III and 10 in stage IV. Of 26 patients, 24 were found with neck tumor, 12 with mediastinum tumor, 11 with spleen infiltration and 5 with B symptom. Four patients were allocated into R(1) group, 12 R(2) group and 10 R(3) group. Eight of 26 with residual disease received radiotherapy, 7 received 20-26 Gy and 1 received 36 Gy. To Jun 2009, 21 (80.76%) of them kept in complete remission (CR) at 10 to 120 months follow-up (average 36 months, and median 31 months). Five cases relapsed (1 of stage III and 4 of stage IV) within 5 to 12 months. Three out of 4 in stage IV with B symptom relapsed. The estimated 5-year overall survival (OS) was 85.9% and EFS was 73.7%.
Conclusion:
The estimated 5-year EFS indicated that protocol HL-98 is reasonable good. Patients of stage I and II can obtain a good prognosis without radiotherapy.
